Britain and America have established a significant bilateral deal that will guarantee no import taxes on British medicine exports entering the US market.
Agreement Details of the Accord
As part of the deal, the UK has committed to raise expenditure on medicines through the NHS. This pledge ensures that import taxes on these vital products will stay at zero for a duration of the next three years.
This agreement comes after recent statements to significantly raise tariffs on branded pharmaceutical products, with figures mentioned up to 100%.
"This deal between the UK reinforces the international landscape for cutting-edge drugs and introduces much-needed balance to U.S.–U.K. medicine commerce," a release said.
Economic Importance
Medicines are one of the UK's most significant goods shipped to the America, which is easily the largest market for leading UK drugmakers.
Trade data show that in the year to the end of last September, the UK sold drugs worth £11.1bn to the US. This amount represented 17.4% of total UK exports in that period.
"This guarantee secures work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary stated.
Key UK Commitments
The agreement entails several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a aim to double total public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must return to the NHS to prevent overspending will be limited at 15%. Last year, rebates exceeded twenty percent.
Industry Background
This agreement follows a long-running dispute between the drug companies and the UK government over medicine costs and regulatory access.
This friction were intensified by assertions that US patients were paying a premium for the equivalent treatments than patients in the UK and Europe.
Over the last 18 months, several major manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been announced toward American operations.
The Science Minister publicly accepted that the NHS needed to spend more on medicines, noting that its expenditure on drugs had shrunk as a proportion of its overall budget over the last ten years.
